Conditions: Branch Retinal Vein Occlusion
Keywords: Macular Edema, Branch Retinal Vein Occlusion, visual impairment
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 455
Healthy volunteers: no

Brief summary:
This study will generate comparative data for 0.5-mg ranibizumab using PRN dosing administered with or without adjunctive laser treatment versus laser photocoagulation (the current standard of care) up to Month 6 in patients with visual impairment due to ME secondary to BRVO. Additionally the results of this study will provide long-term (24-month) safety and efficacy data for ranibizumab, administered with or without adjunctive laser treatment in this indication.

Detailed description:

Arms:
arm 1: Ranibizumab 0.5 mg arm 2: Ranibizumab 0.5 mg + laser arm 3: Laser monotherapy with Ranibizumab 0.5 mg from Month 6

Interventions: intervention 1: Ranibizumab intervention 2: Laser
Intervention descriptions: intervention 1: None intervention 2: laser photocoagulation

Protocol document: